Home Tags Nirogacestat

Tag: nirogacestat

Stamford’s SpringWorks Therapeutics debuts IPO today

The gross proceeds to SpringWorks from the offering are expected to be $162 million.

Readying IPO, SpringWorks Therapeutics names new CFO

The Stamford company says it plans to apply some of the proceeds from its $115 million IPO towards a Phase 3 study of a drug candidate for treating patients with tumors that occur in connective tissue.

FDA fast tracks SpringWorks Therapeutics drug for treatment of tumors

"The fast track designation recognizes that desmoid tumors have a substantial impact on the lives of patients," said Saqib Islam, CEO of SpringWorks Therapeutics.